Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer
- Nada H. Eisa,
- Vincent M. Crowley,
- Asif Elahi,
- Vamsi Krishna Kommalapati,
- Michael A. Serwetnyk,
- Taoufik Llbiyi
- Augusta University,
- University of Notre Dame,
- University of Naples Federico II,
- Baylor College of Medicine,
- Moffitt Cancer Center,
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Low response rates and immune-related adverse events limit the remarkable impact of cancer immunotherapy. To improve clinical outcomes, preclinical studies have shown that combining immunotherapies with N-terminal Hsp90 inhibitors resulted in improved efficacy, even though induction of an extensive heat shock response (HSR) and less than optimal dosing of these inhibitors limited their clinical efficacy as monotherapies. We discovered that the natural product Enniatin A (EnnA) targets Hsp90 and destabilizes its client oncoproteins without inducing an HSR. EnnA triggers immunogenic cell death in triple-negative breast cancer (TNBC) syngeneic mouse models and exhibits superior antitumor activity compared to Hsp90 N-terminal inhibitors. EnnA reprograms the tumor microenvironment (TME) to promote CD8<sup>+</sup> T cell-dependent antitumor immunity by reducing PD-L1 levels and activating the chemokine receptor CX3CR1 pathway. These findings provide strong evidence for transforming the immunosuppressive TME into a more tumor-hostile milieu by engaging Hsp90 with therapeutic agents involving novel mechanisms of action.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Article number
108308Journal (Volume, Issue Number)
iScience (Volume 26, Issue 12)Publication milestones
- Published - 12/15/2023
Publication status
Published - 12/15/2023
Publication IDs
- Scopus: 85176143702
- ORCID: /0000-0002-7711-2858/work/157545211
Publication metrics
Metrics
Fractional count
4
Fractional count
0.20
Fractional count
16
Fractional count
0.80
Fractional count
4
Fractional count
1
PlumX, opens in new tab
Usage
142
Captures
16
Citation count
21
Funding Details
We thank Drs. Lisa Middleton and Rhea-Beth Markowitz for their thorough editing of the manuscript. We are grateful to Dr. Shelli R. McAlpin (University of New South Wales, Sydney, Australia) for providing the SM compounds. We thank the Georgia Cancer Center core facilities, especially the Integrated Genomics and Flow Cytometry shared resources, and the Augusta University Electron Microscopy and Histology cores, for their valuable expertise. This work was supported by NIH R01 grant GM102443-01 and R01CA249178, a Unite in The Fight Against Cancer Award, and Augusta University Startup Funds for A.C.; N.H.E was supported by a government scholarship fund from the Egyptian Cultural and Educational Bureau. V.C. was supported by fellowship award CA212467. A.C. and B.B. conceived and designed experiments. A.C. N.H.E. V.M.C. A.E. V.K.K. M.A.S. T.L. S.L. K.K. Y.J. D.M. A.E.A. S.K.L. F.T.F.T. H.K. and A.D. performed the experiments. A.C. N.H.E. E.C. P.C.R. and D.M. analyzed and interpreted the data. A.C. N.H.E, A.D. and E.C. contributed to the preparation of the manuscript. C.E. A.D. B.B. P.C.R. and H.K. provided reagents. A.C. and Augusta University have a patent (US 11,446,352 B2) related to this work. All other authors have no conflict of interest to declare for this research. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in their field of research or within their geographical location. One or more of the authors of this paper self-identifies as a gender minority in their field of research. We support inclusive, diverse, and equitable conduct of research.
We thank Drs. Lisa Middleton and Rhea-Beth Markowitz for their thorough editing of the manuscript. We are grateful to Dr. Shelli R. McAlpin (University of New South Wales, Sydney, Australia) for providing the SM compounds. We thank the Georgia Cancer Center core facilities, especially the Integrated Genomics and Flow Cytometry shared resources, and the Augusta University Electron Microscopy and Histology cores, for their valuable expertise. This work was supported by NIH R01 grant GM102443-01 and R01CA249178 , a Unite in The Fight Against Cancer Award, and Augusta University Startup Funds for A.C.; N.H.E was supported by a government scholarship fund from the Egyptian Cultural and Educational Bureau . V.C. was supported by fellowship award CA212467.
